Pharmaceutical Mktg (PMRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmaceutical Mktg (PMRX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Lee who wrote ()	6/9/1998 3:12:00 PM
From: Paul Lee	of 11

Pharma Mkting, Cognizant Merger Delayed By Antitrust Review Dow Jones Newswires NEW YORK -- Pharmaceutical Marketing Services Inc.'s (PMRX) merger with a unit of Cognizant Corp. (CZT) will not close before Cognizant's reorganization due to continuing review of the transaction by the Securities and Exchange Commission. As reported, Cognizant filed a Form 10 statement with the SEC related to its plan to establish its IMS Health Inc. unit as a separate public company. Cognizant said its Nielsen Media Research Inc. unit will be the successor company upon completion of the IMS spinoff. In a press release Tuesday, Pharmaceutical Marketing said its shareholders will receive shares of IMS Health at the merger's close. Pharmaceutical Marketing said it is complying with requests from antitrust authorities for information about the merger, but cannot estimate when the review will be completed. IMS Health provides information services to the pharmaceutical and health care industries. Nielsen Media Research provides electronic audience measurement services. Pharmaceutical Marketing Services provides specialized data service to the health care industry.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next